Cell Reports (Mar 2023)
Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma
- Toshiki Ebisudani,
- Junko Hamamoto,
- Kazuhiro Togasaki,
- Akifumi Mitsuishi,
- Kai Sugihara,
- Taro Shinozaki,
- Takahiro Fukushima,
- Kenta Kawasaki,
- Takashi Seino,
- Mayumi Oda,
- Hikaru Hanyu,
- Kohta Toshimitsu,
- Katsura Emoto,
- Yuichiro Hayashi,
- Keisuke Asakura,
- Todd A. Johnson,
- Hideki Terai,
- Shinnosuke Ikemura,
- Ichiro Kawada,
- Makoto Ishii,
- Tomoyuki Hishida,
- Hisao Asamura,
- Kenzo Soejima,
- Hidewaki Nakagawa,
- Masayuki Fujii,
- Koichi Fukunaga,
- Hiroyuki Yasuda,
- Toshiro Sato
Affiliations
- Toshiki Ebisudani
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Junko Hamamoto
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Kazuhiro Togasaki
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Akifumi Mitsuishi
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Kai Sugihara
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Taro Shinozaki
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Takahiro Fukushima
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Kenta Kawasaki
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Takashi Seino
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Mayumi Oda
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Hikaru Hanyu
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Kohta Toshimitsu
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Katsura Emoto
- Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan
- Yuichiro Hayashi
- Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan
- Keisuke Asakura
- Division of Thoracic Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan
- Todd A. Johnson
- Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
- Hideki Terai
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Shinnosuke Ikemura
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Ichiro Kawada
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Makoto Ishii
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Tomoyuki Hishida
- Division of Thoracic Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan
- Hisao Asamura
- Division of Thoracic Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan
- Kenzo Soejima
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Hidewaki Nakagawa
- Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
- Masayuki Fujii
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Koichi Fukunaga
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
- Hiroyuki Yasuda
- Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Corresponding author
- Toshiro Sato
- Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Corresponding author
- Journal volume & issue
-
Vol. 42,
no. 3
p. 112212
Abstract
Summary: Human lung cancer is a constellation of tumors with various histological and molecular properties. To build a preclinical platform that covers this broad disease spectrum, we obtained lung cancer specimens from multiple sources, including sputum and circulating tumor cells, and generated a living biobank consisting of 43 lines of patient-derived lung cancer organoids. The organoids recapitulated the histological and molecular hallmarks of the original tumors. Phenotypic screening of niche factor dependency revealed that EGFR mutations in lung adenocarcinoma are associated with the independence from Wnt ligands. Gene engineering of alveolar organoids reveals that constitutive activation of EGFR-RAS signaling provides Wnt independence. Loss of the alveolar identity gene NKX2-1 confers Wnt dependency, regardless of EGFR signal mutation. Sensitivity to Wnt-targeting therapy can be stratified by the expression status of NKX2-1. Our results highlight the potential of phenotype-driven organoid screening and engineering for the fabrication of therapeutic strategies to combat cancer.